Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-104991
Filing Date
2025-08-07
Accepted
2025-08-07 16:06:21
Documents
67
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ctmx-20250630.htm   iXBRL 10-Q 2926377
2 EX-10.2 ctmx-ex10_2.htm EX-10.2 97720
3 EX-31.1 ctmx-ex31_1.htm EX-31.1 19865
4 EX-31.2 ctmx-ex31_2.htm EX-31.2 19973
5 EX-32.1 ctmx-ex32_1.htm EX-32.1 13868
6 EX-32.2 ctmx-ex32_2.htm EX-32.2 13790
  Complete submission text file 0000950170-25-104991.txt   9826729

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ctmx-20250630.xsd EX-101.SCH 1082481
70 EXTRACTED XBRL INSTANCE DOCUMENT ctmx-20250630_htm.xml XML 1841442
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37587 | Film No.: 251193931
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)